Immuneering Corporation (IMRX) NASDAQ

3.64

-0.045(-1.22%)

Updated at July 30 12:26PM

Currency In USD

Immuneering Corporation

Address

245 Main Street

Cambridge, MA 02142

United States of America

Phone

617 500 8080

Sector

Healthcare

Industry

Biotechnology

Employees

54

First IPO Date

July 30, 2021

Key Executives

NameTitlePayYear Born
Dr. Benjamin J. Zeskind M.B.A., Ph.D.Co-Founder, President, Chief Executive Officer & Director941,3161983
Mr. Robert J. Carpenter M.B.A., M.S.Co-Founder & Chair Emeritus45,0001946
Mr. Harold E. BrakewoodChief Business Officer579,7691966
Mr. Michael D. Bookman J.D.Chief Legal Officer & Secretary689,9591987
Dr. Brett M. Hall Ph.D.Chief Scientific Officer918,1241969
Ms. Mallory Morales CPAPrincipal Financial & Accounting Officer, Chief Accounting Officer and Treasurer01984
Ms. Paula George CPADirector of Accounting & Operations and Assistant Corporate Controller0N/A
Dr. Praveen Nair Ph.D.Head of Translational Pharmacology & Vice President0N/A
Ms. Leah R. NeufeldChief People Officer01973
Dr. Peter King Ph.D.Head of Discovery & Vice President0N/A

Description

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.